Sera Prognostics, Inc. Class A SERA
NASDAQ · United States · Health Services
$2.06-0.03 (-1.44%)
Market open· · USD · Data may be delayed
Prices may be delayed and are for informational purposes only - not investment advice.
Market open· · USD · Data may be delayed
Prices may be delayed and are for informational purposes only - not investment advice.
Total return, dividends included.
Preterm birth affects about 1 in 10 U.S. pregnancies. It's one of the most common pregnancy complications. It's also one nobody warns you about. Yet most expecting mothers never learn their own risk until something goes wrong, because doctors can flag only about 20% of at-risk women using traditional history-based methods. Dr. Thaïs Aliabadi, a board-certified OB-GYN in Los Angeles and co-host of the SHE MD podcast, wants that to change. She says risk is personal and can be identified as early a
Sera Prognostics Inc., The Pregnancy Company® (Nasdaq: SERA), focused on improving maternal and neonatal health by providing innovative pregnancy biomarker information to doctors and patients, announced today that Scott Gleason has been appointed Chief Financial Officer (CFO), effective August 31, 2026.
Where the price sits against its 50- and 200-day moving averages.
Makkler Fair Value, financial health score, analyst view, peers and MakklerAI.
Recent third-party headlines about this company, kept separate from Makkler's own editorial coverage and linking out to the publisher. Accuracy is the publisher's responsibility.